List All Lymphoma Trials

Lymphoma

 

SGN-35 for CD30-positive Malignancies/Previous SGN-35 study (UW09044)
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study

Investigator: Ajay Gopal, MD ;   Conditions: Lymphoma;    Status: Closed;   Study ID: NCT00947856

Brentuximab Vedotin for Relapsed or Refractory CD30+ Lymphoma (FH 7808)
A Pilot Study of Weekly Brentuximab Vedotin in Patients With CD30+ Malignancies Refractory to Every >= 3 Week Brentuximab Vedotin

Investigator: Ajay K. Gopal, MD;   Conditions: Lymphoma;    Status: Closed;   Study ID: NCT01703949

DCDT2980S or DCDS4501A in Combination with MabThera/Rituxan for Relapsed Lymphoma (FH 2649)
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DCDT2980S in Combination With Rituximab or DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-cell Non Hodgkin's Lymphoma

Investigator: Oliver Press, M.D.;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01691898

Two Doses of Fostamatinib for Large B-Cell Lymphoma (UW12019)
A Randomised Double Blind Phase II Trial to Evaluate the Efficacy of Two Doses of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Investigator: Andrei R. Shustov, MD;   Conditions: Diffuse Large B-Cell Lymphoma;    Status: Closed;   Study ID: NCT01499303

TREC for Relapsed or Refractory Lymphoid Malignancies (PSOC 2502)
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies

Investigator: Ajay K. Gopal, MD;   Conditions: Lymphoma;    Status: Closed;   Study ID: NCT01165112

PF-04449913 for Hematologic Malignancies (UW09021)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies

Investigator: Vivian Oehler, M.D,;   Conditions: Hematologic Malignancies;    Status: Closed;   Study ID: NCT00953758

LDK378 for Tumors with ALK Mutation (UW10038)
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Investigator: Laura Chow, MD;   Conditions: Tumors Characterized by Genetic Abnormalities of ALK;    Status: Closed;   Study ID: NCT01283516

SGN-75 for Lymphoma or Renal Cell Carcinoma (SGN75-001)
A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma

Investigator: John Thompson, MD ;   Conditions: Renal Cell Carcinoma, Non-Hodgkin Lymphoma;    Status: Closed;   Study ID: NCT01015911

Zevalin for Newly Diagnosed Diffuse Large B-cell Lymphoma (FH 7779)
A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy (SPI-ZEV-11-301)

Investigator: Ajay K. Gopal, MD;   Conditions: Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma;    Status: Closed;   Study ID: NCT01510184

Combination Chemotherapy + G-CSF + Plerixafor for Lymphoma Patients Undergoing Mobilization of Autologous PBSC (FH 2310)
Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor

Investigator: Leona Holmberg, MD, PhD;   Conditions: Non-Hodgkin's Lymphoma;    Status: Closed;   Study ID: NCT01097057

Radiolabeled Monoclonal Antibody and Chemotherapy Before Stem Cell Transplant for High-Risk Lymphoid Malignancies (2728)
A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies

Investigator: Ajay Gopal, MD;   Conditions: Acute Lymphoid Leukemia (ALL); , Burkitt's Lymphoma; , Hodgkin's Lymphoma; , Leukemia; Lymphoma; , Non-Hodgkin's Lymphoma (NHL); , Mycosis Fungoides/Sezary Syndrome;    Status: Recruiting;   Study ID: NCT01921387

Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma (2639)
Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor

Investigator: David Maloney, MD, PhD;   Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia;    Status: Recruiting;   Study ID: NCT01865617

SGN-35 for Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma - Expanded Access (20100989)
A Treatment-Option Study of Brentuximab Vedotin (SGN-35) in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Investigator: Andrei Shustov, MD;   Conditions: Hodgkin's LymphomaAnaplastic Large-Cell Lymphoma;    Status: Closed;   Study ID: NCT01196208

Open-label Study of Pralatrexate with Vitamin B12 and Folic Acid for Relapsed or Refractory T-cell Lymphoma (6774)
A Phase I, Open-label Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma

Investigator: Andrei Shustov, MD;   Conditions: Cutaneous T-Cell Lymphoma;    Status: Closed;   Study ID: NCT00554827

Chemo Based on PET Scan for Stage I-II Hodgkin Lymphoma (CTSU C50604)
Phase II Trial Of Response-Adapted Chemotherapy Based On Positron Emission Tomography For Non-Bulky Stage I And II Hodgkin Lymphoma

Investigator: Fred Appelbaum, MD;   Conditions: Hodgkin's Lymphoma;    Status: Closed;   Study ID: NCT01132807

ACP-196 in Combination With ACP-319 for B-Cell Malignancies (20142444)
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects with B-cell Malignancies

Investigator: Stephen Smith;   Conditions: Non-hodgkin Lymphoma, Multiple Myeloma;    Status: Recruiting;   Study ID: NCT02328014

Folotyn in Combination With Oral Leucovorin for Peripheral T-Cell Lymphoma (20141037)
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Investigator: Andrei Shustov, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT02106650

Y-90-Ibritumomab Tiuxetan + Reduced-Intensity Allogeneic Transplant for Aggressive B-Cell Lymphoma (FH 2398)
A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma

Investigator: Ajay Gopal, MD;   Conditions: Lymphoma;    Status: Closed;   Study ID: NCT01434472

P276-00 for Relapsed and/or Refractory Mantle Cell Lymphoma (UW09052)
Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma

Investigator: Ajay Gopal, MD;   Conditions: Mantle Cell Lymphoma;    Status: Closed;   Study ID: NCT00843050

Topical SGX301 and Fluorescent Bulb-Light Irradiation for Cutaneous T-Cell Lymphoma (20151086)
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma

Investigator: Michi Shinohara, MD;   Conditions: Lymphoma; Non-Hodgkin (NHL); Cutaneous T-Cell Lymphoma;    Status: Recruiting;   Study ID: NCT02448381

Pralatrexate with CHOP Regimen for Peripheral T-Cell Lymphoma (20151824)
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) for Peripheral T-Cell Lymphoma (PTCL)

Investigator: Andrei Shustov, MD;   Conditions: Lymphoma; Peripheral T-Cell Lymphoma (PTCL);    Status: Recruiting;   Study ID: NCT02594267

MK-3475 with Standard RCHOP Therapy for Diffuse Large B-Cell Lymphoma (9291)
MK-3475 in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Investigator: Stephen Smith, MD;   Conditions: Hematologic Malignancies; Lymphoma, Large B-Cell;    Status: Recruiting;   Study ID: NCT02541565

PF-05082566 (4-1BB agonist mAb) for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)

Investigator: Ajay K. Gopal, MD;   Conditions: Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT01307267

Vorinostat and Combination Chemotherapy With Rituximab for HIV-Related Lymphoma (FH 2483)
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma

Investigator: Ann Woolfrey, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01193842

ACP-196 in Combination with Bendamustine and Rituximab for Mantle Cell Lymphoma (20160991)
A Phase 1b, Multicenter, Open-Label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma

Investigator: Stephen Smith, MD;   Conditions: Lymphoma, Mantle-Cell Lymphoma;    Status: Recruiting;   Study ID: NCT02717624

A Long-term Extension Study of PCI-32765 (Ibrutinib)
A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Investigator: Ajay Gopal, MD;   Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma;    Status: Recruiting;   Study ID: NCT01804686

Bortezomib and Vorinostat Post ASCT for Non-Hodgkin Lymphoma (FH 2292)
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen

Investigator: Leona A. Holmberg, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT00992446

A+AVD vs. ABVD as Frontline Therapy for Hodgkin Lymphoma (UW12044)
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Investigator: Ajay K. Gopal, MD;   Conditions: Hodgkin Lymphoma;    Status: Recruiting;   Study ID: NCT01712490

Bortezomib + Rituximab for Mantle Cell Lymphoma Post Stem Cell Transplant (FH 2620)
A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation

Investigator: Leona A. Holmberg, MD, PhD;   Conditions: Mantle Cell Lymphoma;    Status: Pending;   Study ID: NCT01267812

PCI-32765 (Ibrutinib) + R-CHOP for Newly Diagnosed Large B-Cell Lymphoma (UW13027)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Investigator: Ajay K. Gopal, MD;   Conditions: Lymphoma;    Status: Closed;   Study ID: NCT01855750

GDC-0853 Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (UW13044)
An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0853 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Investigator: Stephen Douglas Smith, MD;   Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia;    Status: Closed;   Study ID: NCT01991184

PF-05082566 (4-1BB agonist mAb) for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)

Investigator: Ajay K. Gopal, MD;   Conditions: Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT01307267

BMS-986016 for Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas (13045)
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

Investigator: Ajay K. Gopal, MD;   Conditions: Hematologic Neoplasms;    Status: Recruiting;   Study ID: NCT02061761

IMO-8400 for Relapsed or Refractory Waldenstrom's Macroglobulinemia (UW14016)
Phase 1/2 Open-Label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Investigator: Edward N. Libby, MD;   Conditions: Waldenstrom's Macroglobulinemia;    Status: Recruiting;   Study ID: NCT02092909

GS-9973 for Relapsed or Refractory Hematologic Malignancies (UW13029)
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

Investigator: Andrei R. Shustov, MD;   Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma;    Status: Recruiting;   Study ID: NCT01799889

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide for Previously Untreated Mantle Cell Lymphoma (E1411)
Intergroup Randomized Phase 2 Four Arm Study In Patients = 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB ? R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV? R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB ? LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV ? LR)

Investigator: Brian Till, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01415752

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide for Relapsed or Refractory Hodgkin Lymphoma (BV-ICE) (9111)
A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

Investigator: Ryan D. Cassaday, MD;   Conditions: Hodgkin Lymphoma;    Status: Recruiting;   Study ID: NCT02227199

Ibrutinib for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (9107)
A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma

Investigator: Ajay K. Gopal, MD;   Conditions: B-Cell Non-Hodgkin Lymphoma;    Status: Pending;   Study ID: NCT02207062

Romidepsin for Maintenance Therapy Post Transplant for T-Cell Non-Hodgkin Lymphoma (9023)
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Investigator: Andrei R. Shustov, MD;   Conditions: T Cell Non-Hodgkin Lymphoma;    Status: Pending;   Study ID: NCT01908777

MPDL3280A + Obinutuzumab for Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma (9162)
A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Investigator: Brian Till, MD;   Conditions: Follicular Lymphoma, B-Cell Lymphoma;    Status: Open;   Study ID: NCT02220842

Combination Chemotherapy w w/o Auto Transplant for Central Nervous System B-Cell Lymphoma (CALGB 51101)
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma

Investigator: Maciej M. Mrugala, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01511562

Pembrolizumab (MK-3475) for Relapsed/Refractory Mycosis Fungoides/Sézary Syndrome (CC CITN-10)
A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sézary Syndrome

Investigator: Andrei R. Shustov, MD;   Conditions: Mycosis Fungoides , Sezary Syndrome;    Status: Closed;   Study ID: NCT02243579

Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma (UW15002)
An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

Investigator: Stephen Smith, MD;   Conditions: Mantle-Cell Lymphoma, Large B-Cell Diffuse Lymphoma, Follicular Lymphoma;    Status: Pending;   Study ID: NCT02413489

Enzalutamide for Relapsed or Refractory Mantle Cell Lymphoma (9340)
Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide

Investigator: Ajay K. Gopal, MD;   Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma;    Status: Recruiting;   Study ID: NCT02489123

INCB054329 for Advanced Malignancies (UW15024)
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

Investigator: Ryan D. Cassaday, MD;   Conditions: Advanced Cancer;    Status: Recruiting;   Study ID: NCT02431260

Nivolumab + Brentuximab Vedotin for Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression
A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)

Investigator: Andrei R. Shustov, MD;   Conditions: Non-Hodgkin's Disease;    Status: Recruiting;   Study ID: NCT02581631

Ixazomib Citrate + Rituximab for Indolent B-cell Non-Hodgkin Lymphoma
A Window Study of Ixazomib in Untreated Indolent B-NHL

Investigator: Ajay K. Gopal, MD;   Conditions: Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia;    Status: Recruiting;   Study ID: NCT02339922

Romidepsin and Lenalidomide for Untreated Peripheral T-Cell Lymphoma (CC9518)
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL

Investigator: Andrei R. Shustov, MD;   Conditions: T-cell Lymphoma;    Status: Pending;   Study ID: NCT02232516